Valproate and Bipolar Disorder: What to Know About Depakote

If you’ve been prescribed valproate — or its brand-name version, Depakote — it’s natural to want to understand exactly what you’re taking. Why this medication? What does it actually do in the brain? What side effects should you realistically expect? And what about the warnings you’ve read online?

These are reasonable questions, and they deserve direct answers. Valproate has been used in bipolar disorder since the 1970s, and there’s now a substantial evidence base behind it. It’s also a medication with real trade-offs that vary significantly depending on who is taking it. This article walks through what the research actually says — about how it works, when it’s used, what to watch for, and what the evidence says about its safety, particularly for women.

If you’re weighing medication options and want a clinical perspective on what might work for your specific situation, Sway Health offers consultations with bipolar-specialized clinicians via telehealth. That kind of individualized conversation is where decisions like this actually get made well.

What Is Valproate — and How Does It Work?

Valproate — valproic acid — is the active compound that goes by several brand names: Depakene (valproic acid, original form), Depakote (divalproex sodium, enteric-coated for better GI tolerance), and Depakote ER (extended release, once-daily dosing). All deliver the same active ingredient; the differences are in formulation and tolerability profile.

It was originally developed as an anticonvulsant for epilepsy. Its use in bipolar disorder emerged from observations that certain anticonvulsants had mood-stabilizing properties — and over decades of clinical research, valproate’s role in bipolar treatment has become well-established.

How it works involves multiple overlapping mechanisms. Research confirms it primarily works by increasing brain concentrations of GABA — gamma-aminobutyric acid, the brain’s primary inhibitory neurotransmitter — through increased GABA synthesis, decreased GABA breakdown, and inhibition of the enzymes that clear it. It also weakly blocks sodium ion channels. This combination of mechanisms may be part of why valproate appears effective across different bipolar episode types, not just mania.

What the Evidence Says About Valproate for Bipolar Disorder

For Acute Mania

The evidence for valproate in acute mania is strong. A Cochrane review of 25 trials including 3,252 participants found high-quality evidence that valproate produces significantly better response rates than placebo (45% vs. 29%). Critically, the same review found no significant difference in response rates between valproate and lithium — the long-established gold standard for bipolar disorder.

A 2024 overview of 26 systematic reviews covering 31 randomized controlled trials and 4,376 participants confirmed these findings, showing valproate significantly more effective than placebo for acute mania (RR=1.42; 95% CI: 1.19–1.71), with no significant differences from lithium in most outcomes.

For Bipolar Depression

The evidence for valproate in bipolar depression is meaningful but less robust than for mania. The 2024 overview found valproate more effective than placebo in reducing depressive symptoms (OR=2.80; 95% CI: 1.26–6.18), based on seven randomized controlled trials involving 399 participants. A Cochrane-quality systematic review concluded that valproate was effective for acute bipolar depression and well-tolerated.

These are smaller trial sets than the mania data, but they support valproate’s use as one option for the depressive phase.

For Maintenance and Relapse Prevention

For long-term maintenance, a 2021 systematic review and meta-analysis found valproate significantly more effective than placebo in preventing new bipolar episodes of either mania or depression, with no significant differences from lithium, second-generation antipsychotics, or other anticonvulsants. The 2024 overview confirmed a relapse prevention benefit versus placebo (RR=0.63; 95% CI: 0.48–0.83).

Key Takeaway: Valproate has well-established evidence across all three phases of bipolar disorder — acute mania, depressive episodes, and relapse prevention. Its efficacy is broadly comparable to lithium in most head-to-head comparisons, with the choice between them often coming down to individual tolerability and clinical factors.

When Valproate May Be Considered Instead of Lithium

Valproate and lithium are both first-line options for bipolar disorder per CANMAT/ISBD guidelines, the most widely referenced international guidelines for bipolar treatment. The choice between them isn’t universal — it depends on your specific situation.

Circumstances where a clinician might lean toward valproate include:

• Rapid cycling presentation — some evidence suggests valproate may have advantages in this pattern
• Mixed features or dysphoric mania — valproate’s broader mechanism profile is often considered here
• When lithium monitoring is a barrier — lithium requires regular blood level checks and has a narrow therapeutic window; valproate’s monitoring is less intensive for some patients
• Mania-predominant pattern — the evidence base for valproate in mania is particularly strong

It’s worth noting what valproate is generally not recommended for: our guide to what the research says about lithium and our overview of mood stabilizers for bipolar disorder both cover how these decisions get made in clinical practice. The short version: these aren’t rules, they’re clinical considerations that a bipolar specialist weighs alongside your full history.

Side Effects You Should Know About

Common Side Effects

The side effects you’re most likely to encounter with valproate are:

• Weight gain — one of the more frequently reported issues; mechanism isn’t fully understood, but it’s real enough to factor into decision-making
• Hair thinning and changes in hair texture — documented in clinical research; zinc or selenium supplementation may help minimize this; always discuss with your provider before adding supplements
• Tremor — fine hand tremor is common, particularly at higher doses; often manageable with dose adjustment
• GI upset — nausea, stomach discomfort, especially early in treatment; the Depakote (divalproex) formulation is enteric-coated specifically to reduce this; Depakote ER can further reduce GI symptoms for some patients
• Sedation — some people experience fatigue or cognitive slowing, particularly early on

Clinical case literature notes that many of these effects are dose-related and may improve with adjustments. Hair changes, in particular, often improve over time or respond to supplementation. None of these should be dismissed, but most are addressable in a collaborative relationship with a knowledgeable prescriber.

Serious Side Effects (Less Common)

• Liver toxicity — valproate can cause elevations in liver enzymes; this is why baseline liver function tests (LFTs) and periodic monitoring are standard practice. Serious liver toxicity is rare in adults, but it’s why the monitoring exists.
• Thrombocytopenia — reduced platelet count; monitored via regular complete blood count (CBC)
• Metabolic acidosis — less common; part of standard monitoring

If you’re starting valproate, this monitoring schedule isn’t alarming — it’s just careful prescribing. Expect baseline labs and periodic follow-up bloodwork as part of routine care.

If you’ve been curious about how medication decisions like this are made with clinical precision, exploring how bipolar-specialized care works can help frame the broader picture.

Valproate and Pregnancy — A Conversation That Matters

This section is important, and it’s written with care — not to alarm, but because this is information you deserve to have clearly and directly.

The FDA has issued a safety communication on valproate use during pregnancy. Children born to mothers who took valproate products while pregnant may have impaired cognitive development. Research confirms valproate’s teratogenic potential — including risk of neural tube defects and other congenital malformations when exposure occurs during pregnancy. NCBI’s MotherToBaby resource provides a comprehensive evidence review of valproate in pregnancy for those who want to go deeper.

Beyond pregnancy itself, there are reproductive concerns worth knowing about. A 2026 nationwide cohort study published in PubMed found that women taking valproate have an elevated risk of polycystic ovary syndrome (PCOS) — a hormonal condition that affects menstrual cycles and fertility. The study’s authors reinforced existing recommendations to avoid valproate in women of reproductive age when alternative options exist.

What this means practically:

• If you’re a woman of reproductive age who is sexually active, this conversation with your prescriber is essential — not optional
• Effective contraception is typically recommended if valproate is continued
• There are alternative mood stabilizers with better safety profiles in pregnancy (lamotrigine, for example, is a common consideration)

This doesn’t mean valproate can’t be the right choice for some women — it means the decision requires a full discussion of your reproductive plans, contraceptive use, and alternative options. Understanding how bipolar disorder affects women differently provides additional context on why these conversations matter.

Drug Interactions — Especially With Lamotrigine

If you’re prescribed both valproate and lamotrigine (Lamictal), this is a clinically significant interaction that your prescriber needs to manage carefully.

Research published in peer-reviewed literature established that valproate markedly increases the half-life of lamotrigine and decreases its clearance from the body. In practice, this means valproate roughly doubles the concentration of lamotrigine in the bloodstream. When the two are co-prescribed, lamotrigine doses must be approximately halved to avoid toxicity.

This interaction is sometimes used deliberately — combining valproate and lamotrigine can be effective for treatment-resistant bipolar depression — but it requires careful dose management and monitoring.

Practical note: if you’re on valproate and are prescribed anything new — by any provider, including non-psychiatric ones — mention the valproate. Drug interactions are manageable when they’re anticipated.

Monitoring Requirements

Valproate requires regular monitoring as part of responsible prescribing. You should expect:

• Liver function tests (LFTs): Baseline before starting, then periodically (typically every 6-12 months for stable patients)
• Complete blood count (CBC): Monitors for thrombocytopenia (platelet reduction)
• Valproate serum levels: Therapeutic range is typically 50–125 mcg/mL, though clinical judgment determines the right target for your situation

This monitoring isn’t a sign something is wrong. It’s how a careful prescriber stays ahead of any emerging issues and confirms the medication is at the right level for you.

Frequently Asked Questions

Is valproate the same as Depakote?

Depakote is a brand name for divalproex sodium — a formulation of valproate that’s enteric-coated to reduce gastrointestinal side effects. Depakene is another brand name for valproic acid in its original form. Depakote ER is the extended-release version. All three deliver the same active compound, valproate, and have similar clinical profiles; they differ primarily in how they’re absorbed and tolerated.

How does valproate compare to lithium for bipolar disorder?

In head-to-head clinical trials, valproate and lithium have broadly comparable efficacy for acute mania and maintenance. Neither is universally “better” — the choice depends on factors including your episode type, tolerability, monitoring preferences, and whether you’re a woman of reproductive age. What the research says about lithium covers lithium’s specific evidence base in depth.

Can I take valproate if I’m a woman of childbearing age?

This requires a direct conversation with your prescriber. Due to the risks of neural tube defects and cognitive impairment in children exposed to valproate during pregnancy, current clinical guidance generally recommends avoiding valproate in women of reproductive age when alternatives are available. If valproate is the best option for your specific situation, effective contraception and close monitoring are part of the plan. Alternatives like lamotrigine may be more appropriate — this is exactly the kind of individualized discussion a bipolar specialist is equipped to have.

Understanding Your Medication Is Part of Good Care

Valproate is a well-established, evidence-backed medication for bipolar disorder. It works across all phases — mania, depression, and maintenance. It has real side effects that deserve honest discussion, and real safety considerations that require careful management, particularly for women. And like any medication in bipolar disorder, it works best as part of a care plan that accounts for your complete picture — not just a diagnosis.

If you have questions about valproate, your current regimen, or whether your medication plan is actually built for bipolar disorder specifically, a consultation with a bipolar-specialized clinician can give you a clearer picture.

Sway Health offers bipolar-specialized care entirely via telehealth — medication management, ongoing coordination, and the kind of precision prescribing that treats your bipolar disorder as its own condition, not a variant of something else.